Merus logo.jpg
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
04 mars 2024 08h00 HE | Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus logo.jpg
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
28 févr. 2024 16h15 HE | Merus N.V.
-   Petosemtamab in 1L HNSCC in combination with pembrolizumab initial interim clinical data planned for 2Q24; preparing for a potential phase 3 trial -   Petosemtamab in 2L+ HNSCC phase 3 trial...
Merus logo.jpg
Merus nimmt an bevorstehenden Investorenkonferenzen teil
31 janv. 2024 14h06 HE | Merus N.V.
UTRECHT, Niederlande, und CAMBRIDGE, Mass., USA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), ein Unternehmen im Bereich der klinischen Onkologie, das innovative multispezifische...
Merus logo.jpg
Merus annonce la tenue d’une série de conférences auprès des investisseurs
31 janv. 2024 14h06 HE | Merus N.V.
UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 31 janv. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une société spécialisée dans l’oncologie au stade clinique développant des anticorps de...
Merus logo.jpg
Merus to Participate in Upcoming Investor Conferences
31 janv. 2024 08h00 HE | Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus logo.jpg
Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023
02 déc. 2023 20h40 HE | Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing...
Merus logo.jpg
Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update
02 nov. 2023 16h12 HE | Merus N.V.
– Petosemtamab in combination with Keytruda 1L initial interim clinical data planned for 1H24; 2L+ HNSCC monotherapy clinical update planned 2024 – Zeno interim clinical data continue to show robust...
Merus logo.jpg
Merus to Participate in Upcoming Investor Conferences
01 nov. 2023 08h00 HE | Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus logo.jpg
Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer
23 oct. 2023 07h30 HE | Merus N.V.
- 37% ORR and 14.9 months median DOR in 78 evaluable NRG1+ NSCLC patients - 42% ORR and 9.1 months median DOR in 33 evaluable NRG1+ PDAC patients - Sufficient clinical data expected in 1H24 to...
Merus logo.jpg
Merus Announces Business Update Conference Call
15 oct. 2023 19h58 HE | Merus N.V.
Zeno interim clinical data continues to show robust efficacy in NRG1+ NSCLC and PDAC: Sufficient clinical data expected in 1H24 to support potential BLA submissions Petosemtamab 2L+ HNSCC phase 3...